GLP-1 Response
Before BARI-STEP, semaglutide 2.4 mg had not been tested in a randomized clinical trial for poor clinical weight response after bariatric surgery. Prior liraglutide trials supported GLP-1 receptor agonist therapy after bariatric surgery. L…
1 sources - 5 claims
Before BARI-STEP, semaglutide 2.4 mg had not been tested in a randomized clinical trial for poor clinical weight response after bariatric surgery. Prior liraglutide trials supported GLP-1 receptor agonist therapy after bariatric surgery. Lower meal-stimulated circulating GLP-1 has been associated with poorer bariatric weight-loss responses. The trial suggests pharmacological GLP-1 receptor agonism may override mechanisms related to blunted endogenous GLP-1 response.